DYRK1A-dosage imbalance perturbs Nrsf/Rest levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome

A transchromosomic mouse model of the Down syndrome (DS) is employed to study the impact of the reduced expression of the Nrsf/Rest levels on the individual. The analysis proves that an imbalance in the DYRK1A-dosage leads to a reduction in the REST levels, which in turn deregulates pluripotency and embryonic stem cell fate in DS in the studied models.